The mechanisms of action involved in these therapeutic processes are not well understood; however, it is known that DNAhsp65 stimulates MyD88 signaling, and that CpG activates Fas molecules, culminating in IFN-γ and IL-10 production and reducing allergy (81). The gene discussed is MYD88; the disease is Allergy.